- Home
- DT vs RPRX Comparison
DT vs RPRX Comparison
Compare DT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DT | RPRX |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 16.2B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DT | RPRX |
|---|---|---|
| Price | $44.44 | $39.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 3 |
| Target Price | ★ $61.43 | $46.00 |
| AVG Volume (30 Days) | 3.8M | ★ 4.3M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | ★ 208.33 | N/A |
| EPS | 1.66 | ★ 1.75 |
| Revenue | $1,852,532,000.00 | ★ $2,349,844,000.00 |
| Revenue This Year | $20.68 | $37.13 |
| Revenue Next Year | $14.73 | $1.48 |
| P/E Ratio | $26.70 | ★ $22.68 |
| Revenue Growth | ★ 18.50 | 3.70 |
| 52 Week Low | $39.30 | $24.05 |
| 52 Week High | $63.00 | $41.24 |
Technical Indicators
Market Signals| Indicator | DT | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 57.50 |
| Support Level | $43.63 | $39.24 |
| Resistance Level | $45.41 | $40.50 |
| Average True Range (ATR) | 1.19 | 0.91 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 42.80 | 76.02 |
Price Performance
Historical ComparisonAbout DT Dynatrace Inc.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.